486 related articles for article (PubMed ID: 26914909)
1. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Kiarie J; Ronald A; Baeten JM;
J Acquir Immune Defic Syndr; 2016 Apr; 71(4):374-80. PubMed ID: 26914909
[TBL] [Abstract][Full Text] [Related]
2. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
3. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
Liegeon G; Antoni G; Pialoux G; Capitant C; Cotte L; Charreau I; Tremblay C; Cua E; Senneville E; Raffi F; Meyer L; Molina JM;
J Int AIDS Soc; 2020 Feb; 23(2):e25420. PubMed ID: 32086878
[TBL] [Abstract][Full Text] [Related]
4. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
Petruccelli KCS; Baía-da-Silva DC; Val F; Valões MS; Cubas-Vega N; Silva-Neto AV; Sampaio V; Alencar A; Pecoits-Filho R; Moreira RC; Cardoso SW; Moreira RI; Leite IC; Madruga JV; Kallas EG; Alencastro PR; Hoagland B; Grinsztejn B; Santos VGV; Lacerda MVG
AIDS Res Ther; 2022 Feb; 19(1):12. PubMed ID: 35209929
[TBL] [Abstract][Full Text] [Related]
5. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
6. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
[TBL] [Abstract][Full Text] [Related]
7. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
Jotwani V; Scherzer R; Glidden DV; Mehrotra M; Defechereux P; Liu A; Gandhi M; Bennett M; Coca SG; Parikh CR; Grant RM; Shlipak MG
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):169-174. PubMed ID: 29767638
[TBL] [Abstract][Full Text] [Related]
8. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
Mandala J; Nanda K; Wang M; De Baetselier I; Deese J; Lombaard J; Owino F; Malahleha M; Manongi R; Taylor D; Van Damme L
BMC Pharmacol Toxicol; 2014 Dec; 15():77. PubMed ID: 25539648
[TBL] [Abstract][Full Text] [Related]
9. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
[TBL] [Abstract][Full Text] [Related]
10. Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service.
Drak D; Barratt H; Templeton DJ; O'Connor CC; Gracey DM
PLoS One; 2019; 14(1):e0210106. PubMed ID: 30653509
[TBL] [Abstract][Full Text] [Related]
11. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
Solomon MM; Lama JR; Glidden DV; Mulligan K; McMahan V; Liu AY; Guanira JV; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Burns DN; Grant RM;
AIDS; 2014 Mar; 28(6):851-9. PubMed ID: 24499951
[TBL] [Abstract][Full Text] [Related]
12. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
Kasonde M; Niska RW; Rose C; Henderson FL; Segolodi TM; Turner K; Smith DK; Thigpen MC; Paxton LA
PLoS One; 2014; 9(3):e90111. PubMed ID: 24625530
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
[TBL] [Abstract][Full Text] [Related]
15. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Jose S; Hamzah L; Campbell LJ; Hill T; Fisher M; Leen C; Gilson R; Walsh J; Nelson M; Hay P; Johnson M; Chadwick D; Nitsch D; Jones R; Sabin CA; Post FA;
J Infect Dis; 2014 Aug; 210(3):363-73. PubMed ID: 24585896
[TBL] [Abstract][Full Text] [Related]
16. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
Trang TP; Dong BJ; Kojima N; Klausner JD
Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
[TBL] [Abstract][Full Text] [Related]
17. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
Solomon MM; Schechter M; Liu AY; McMahan VM; Guanira JV; Hance RJ; Chariyalertsak S; Mayer KH; Grant RM;
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):281-6. PubMed ID: 26413853
[TBL] [Abstract][Full Text] [Related]
18. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
[TBL] [Abstract][Full Text] [Related]
19. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
[TBL] [Abstract][Full Text] [Related]
20. HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.
Ascher SB; Scherzer R; Estrella MM; Shigenaga J; Spaulding KA; Glidden DV; Mehrotra ML; Defechereux P; Gandhi M; Grant RM; Shlipak MG; Jotwani V
AIDS; 2020 Apr; 34(5):699-706. PubMed ID: 31794523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
